1. Market Research
  2. > Healthcare
  3. > Diagnostics Market Trends
  4. > Vital Signs - The Analyst's Perspective - April 2015 Issue

Vital Signs - The Analyst's Perspective - April 2015 Issue

  • May 2015
  • -
  • Frost & Sullivan
  • -
  • 6 pages

Summary

Table of Contents

Scope

This issue of Vital Signs, released on May 12, 2015, discusses Roche's acquisition of CAPP Diagnostics, IBM's announcments of deals with Apple, Johnson & Johnson, and Medtronic, 2014 US prescription drug spending trends, and DuPont's acquisition of Taxon Biosciences.This issue of Vital Signs, released on May 12, 2015, discusses Roche's acquisition of CAPP Diagnostics, IBM's announcments of deals with Apple, Johnson & Johnson, and Medtronic, 2014 US prescription drug spending trends, and DuPont's acquisition of Taxon Biosciences.

Roche Acquires CAPP Diagnostics: A Step Up in its Genomics Game Source: NASDAQ, April 14, 2015

The diagnostics and pharmaceutical giant Roche recently announced the acquisition of privately held CAPP diagnostics. This is one of many next-generation sequencing companies absorbed by Roche. The acquisition is aligned with its vision to expand on its next-generation sequencing diagnostics capabilities, especially in oncology. CAPP has a ground-breaking, non-invasive liquid technology to detect circulating tumor DNA (ctDNA) with just a drop of blood. This acquisition not only places Roche in a strong position for non-invasive cancer detection, but also has the potential to provide valuable clinical trial support for its pharmaceutical and oncology drug pipelines.

The Analyst’s Perspective by Aish Vivekanandan, Industry Analyst, Life Sciences, North America

Roche has been steadily acquiring genomics companies like Signature Diagnostics, Bina Technologies and Genia Technologies to build technologies and offerings in the next-generation sequencing market, particularly on the clinical side. With Roche’s decreasing market shares over the years in the next-generation sequencing space, the company is hoping to get back in the game with these technology acquisitions.

These acquisitions come as no surprise as Roche suffered heavy blows when two of its clinical studies for breast cancer and Alzheimer’s disease failed, causing the largest stock backlash in a decade. The company has been scrambling to rectify the situation, turning to the promising next-generation sequencing market, not just in the research space, but also in drug discovery and having a deeper understanding of disease.

In addition to this, Roche has been trying to find the best differentiating system in the market, and CAPP has the best technology of the three recent acquisitions. For Roche, differentiation of its product is key in competing with market leaders Illumina and Life Technologies. CAPP Diagnostics’ technology is a catch in terms of product differentiation, but only time will tell if Roche can achieve a highly competitive product following these costly purchases.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
Get This Report
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
2017 Europe Cancer Diagnostics Market: Sales Forecasts and Strategies, Supplier Shares--Emerging Tumor Markers, Technologies and Opportunities

2017 Europe Cancer Diagnostics Market: Sales Forecasts and Strategies, Supplier Shares--Emerging Tumor Markers, Technologies and Opportunities

  • $ 36000
  • Industry report
  • February 2017
  • by Venture Planning Group

This new 31-country report from VPGMarketResearch.com is available by country, market segment, section, or individual test. This report is designed to assist diagnostics industry executives, as well as ...

2017 Cancer Diagnostics Market Segmentation Analysis: Cancer Clinics, Commercial Labs, Hospitals, Physician Offices--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains

2017 Cancer Diagnostics Market Segmentation Analysis: Cancer Clinics, Commercial Labs, Hospitals, Physician Offices--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains

  • $ 21100
  • Industry report
  • March 2017
  • by Venture Planning Group

Complete report $34,500.  DataPack (test volumes, sales forecasts, supplier shares) $21,100.  The report is available by country, section, market segment, and can be custom-tailored to your specific ...

Cancer Diagnostics 2021: Supplier Shares and Strategies, Country Segment Forecasts, Tehnology Trends, Emerging Opportunities--Tumor Markers, Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains

Cancer Diagnostics 2021: Supplier Shares and Strategies, Country Segment Forecasts, Tehnology Trends, Emerging Opportunities--Tumor Markers, Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains

  • $ 21100
  • Industry report
  • March 2017
  • by Venture Planning Group

Complete report $34,750.  DataPack (test volumes, sales forecasts, supplier shares) $21,100.  The report is available by country, section, market segment, and can be custom-tailored to your specific ...


Download Unlimited Documents from Trusted Public Sources

Diagnostics Forecast in the US

  • March 2017
    2 pages
  • United States  

View report >

Diagnostics Markets in the US

  • March 2017
    3 pages
  • Diagnostics  

  • United States  

View report >

Diagnostics Forecast in the US

  • February 2017
    2 pages
  • Diagnostics  

    Cancer  

    Health Care Pro...  

  • United States  

View report >

Related Market Segments :

Diagnostics

ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.